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Material and Methods: All patients who underwent surgery 
for NSCLC with pathologically confirmed N1 disease at the 
Spedali Civili Hospital of Brescia between 2001-2011 were 
identified. Patients with positive surgical margins, 
undergoing neoadjuvant treatment or PORT were excluded. 
LR was defined as first event of recurrence at the surgical 
bed, ipsilateral hilum or mediastinum, other sites were 
considered as DM. Kaplan-Meier actuarial estimates of overall 
survival (OS), progression free survival (PFS), freedom-from 
LR (FFLR) and freedom-from DM (FFDM) in different 
subgroups were compared with the log-rank test. The Cox 
proportional hazard regression model was used for 
multivariate analysis. 
 
Results: Among 285 patients who underwent surgery during 
the interval, 202 met the inclusion criteria. Clinical 
pathological, treatment and nodal factors are reported in 
table 1. Twenty four percent received adjuvant 
chemotherapy. The median follow-up was 39 months. The 
total number of recurrences was 118 (64.4%): 44 (24%) and 74 
(40.4%) for LR and DM, respectively. 5-year OS and PFS rates 
were 39,2% and 33,3%, respectively. Patients with 
recurrences experienced a statistically worse OS than 
patients without recurrences (p<0.001) and patients with DM 
had in turn OS rates significantly worse than those with LR 
(Figure 1). At multivariate analysis, extra capsular extension 
(ECE) (RR 2.10 p 0.01) and lymph nodal ratio (LNR)> 0:15 (RR 
1.68, p = 0.015) were associated with a worse PFS. ECE and 
LNR> 0,15 were significantly related to a worst FFLR (RR 3.04 
and 4.42, respectively), adenocarcinoma to an unfavorable 
FFDM (RR 1.97, p = 0.013). 
 
 
 
 
Conclusion: LR are common in pN1 NSCLC patients. Nodal 
factors as high LNR and ECE can predict an increased risk of 
worse FFLR and PFS. Prospective data on selected patients, 
treated with modern radiotherapy techniques, need to be 
collected to re-evaluate the role of radiotherapy. 
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Purpose or Objective: To verify adequacy of dose volume 
constraints reported in literature about stereotactic 
radiotherapy (SBRT) and radiosurgery of thoracic area. This 
study is based on the toxicity recorded in organs at risk 
(OARs) of patients enrolled in dose-escalation trials. 
 
Material and Methods: This is a retrospective study 
evaluating treatment plans of neoplasms in thoracic area. All 
55 patients were treated between November 2009 and 
December 2013 using SBRT (37 pt) or SBRS (18 pt). Prescribed 
doses were 30-35 Gy in 5 fractions in SBRS treatments and 16-
28 Gy in single fraction in SBRS treatments. All patients 
underwent radiotherapy with V-MAT technique. Main OARs 
were heart, oesophagus, and ribs with suggested Dmax of 35 
Gy, 32.5 Gy and 32.5 Gy in SBRT treatment, respectively, and 
22 Gy, 15 Gy and 30 Gy in SBRS treatment, respectively. 
Plans were evaluated by DVH analysis. Dosimetric data were 
compared with clinical data on early and late toxicity.  
 
 
 
Results: SBRT treatment: considering heart, oesophagus and 
ribs, Dmax constraints were exceeded in 7/37 patients 
(18.9%), 4/37 (10.8%) and 16/37 (43.2%) respectively. In 
these patients results about OARs were as follow: heart Dmax 
36.6-50 Gy, V35 0.5-4.7 cc; oesophagus Dmax 35.7-41.3 Gy, 
V32.5 0.1-0.9cc; ribs Dmax 35.7-52.5 Gy, V32.5 0.1-7.9cc. 
SBRS treatment: dose on heart and ribs exceeded Dmax 
constraints in 1/18 patients (5.6%) with a Dmax of 23.3Gy 
(V22=0.6cc) and 33.6Gy (V30=0.3cc) respectively. With a 
median follow up of 18 months considering SBRT treatment 
and 16 months considering SBRT, no Grade >2 (CTCAE 4.3), 
early or late toxicity of heart or ribs was reported. In SBRT 
group, 1 grade 2-oesophagus toxicity in a patient exceeding 
DMax constraint was registered. 
 
Conclusion: Patients irradiated did not develop severe 
toxicity on heart, oesophagus, and ribs although the 
administered doses were above constrains proposed in 
literature. A prolonged follow up and a larger population are 
needed to confirm the safety of dose-volume constraints 
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other than those reported in literature about SBRT and SBRS 
on abdominal area. 
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Purpose or Objective: To assess clinical feasibility, local 
control and toxicity of deep inspiratory breath hold (DIBH) 
technique for delivery of SABR for large and mobile tumors of 
lung and liver. 
 
Material and Methods: All patients suitable to undergo SABR, 
underwent respiratory training consisting of DIBH on demand 
for 15-25 seconds at a time. Patients underwent 2 sets of 
immobilization and imaging, one in DIBH phase and other in 
free breathing (FB) phase. Respiratory monitoring was 
performed using Varian RPM system and a 4mm gating 
threshold window was allowed. Set-up verification was 
performed using KV imaging and gated cone beam CT both 
taken in DIBH. All patients were planned with 2-4 arc VMAT 
using 6MV flattening filter free (FFF) photon beams to a dose 
of 60Gy in 5 fractions. 
 
Results: 12 patients of lung tumors and 9 patients of liver 
tumors were treated with DIBH based SABR. In patients with 
lung tumors, DIBH resulted in 1.53 times higher mean lung 
volumes (3937 cc vs. 2576 cc, p=0.003). Compared to ITV 
based contours, PTV volumes were 1.48 times smaller for 
lung and 1.38 times smaller for liver tumors in DIBH CT 
compared to FB CT (36.15 cc vs. 53.83 cc, p=0.002, 57.76cc 
vs. 79.78, p=0.03). All the plans accepted for delivery met 
the standard criteria (ROSEL for lung and RTOG 1112 for 
liver) for both target and OAR constraints. On an average, 
V20 was reduced by 30%(18-38) in DIBH plans compared to FB 
plans. Time taken to deliver each session in DIBH phase with 
FFF beams was longer by an average of 2 minutes due to 
interruptions (maximum 4 interruptions/arc each lasting <10 
seconds). Mean setup errors in cm quantified on CBCT were 
0.1, 0.2 and 0.1 in vertical, longitudinal and lateral 
dimensions respectively and a uniform margin (based on Van 
Herk's formula) of 4mm appears to be safe. Except for 1 
patient with symptomatic grade 2 pneumonitis and 1 patient 
with grade 2 chest wall pain, none had any major toxicities. 
With a median follow-up of 16 months, 18 month local 
control was 95%.  
 
Conclusion: DIBH based SABR is clinically feasible and 
effective and should be considered standard for treating 
mobile and especially large tumors of lung and liver provided 
patient is suitable for treatment with DIBH technique. DIBH-
CBCT based verification appears to be reproducible and 
effective to reduce setup errors. A margin of 4 mm appears 
to be safe in DIBH setting with 4 mm gating threshold 
window. Despite minimal increase in treatment time, DIBH is 
an effective way to deliver high throughput high quality 
SABR. 
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Purpose or Objective: We aimed to establish the model 
predicting radiation-induced pulmonary function change after 
postoperative radiotherapy (PORT) in non-small cell lung 
cancer (NSCLC). 
 
Material and Methods: From March 2003 to December 2011, 
37 patients with NSCLC who underwent PORT were analyzed. 
All patients took the forced expiratory volume in 1 second 
(FEV1) at the beginning of PORT and follow-up FEV1 within 6-
36 months after the completion of PORT. We calculated 
mean lung dose (MLD) as a dosimetric parameter of the lung. 
Simple linear correlation and regression model were 
implemented to establish the prediction model between MLD 
and radiation-induced pulmonary function change. 
 
Results: The median absolute value of FEV1 at the beginning 
of PORT, and follow-up FEV1 were 1.76 L (range, 0.90-
3.05),and 1.66 L (range, 0.93-3.08), respectively. Radiation-
induced pulmonary function change (follow-up FEV1 minus 
FEV1 at beginning of PORT) ranged from -0.71 to 0.40 L 
(median, 0.06). The median MLD of PORT was 12.3 Gy (range, 
0.5-20.4). Radiation-induced FEV1 change and MLD showed 
statistically significant correlation (correlation coefficient = -
0.357, p = 0.030). PORT-induced FEV1 change could be 
predicted by simple linear regression model [FEV1 change (L) 
= 0.295 – 0.026 MLD (Gy)]. 
 
Conclusion: Radiation-induced FEV1 change was significantly 
correlated with MLD in patients with NSCLC who underwent 
surgery followed by PORT. Follow-up FEV1 after the 
completion of PORT can be predicted by simple linear 
regression model using this correlation. 
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Purpose or Objective: The benefits of addition of whole 
brain radiotherapy (WBRT) to stereotactic radiotherapy (SRT) 
with respect to overall survival of patients with brain 
metastases from non-small cell lung cancer (NSCLC) are 
unclear. Most of the published studies addressing this issue 
recruited the patients with diverse histology and primary 
sites, with only few focusing on NSCLC. We addressed this 
issue by evaluating institutional experience in efficacy of SRT 
plus WBRT vs. SRT alone or WBRT alone in patients with 
NSCLC. 
 
Material and Methods: The analysis encompassed 143 
patients with brain metastases from NSCLC, including 65 with 
squamous-cell cancer (45.5%), 53 adenocarcinoma (37.1%), 25 
NOS (17.4%). SRT alone was used in 52 patients (36.4%), 
WBRT alone in 33 patients (23.1%) and WBRT plus SRT in 58 
patients (40.5%). Two chief subgroups were considered: those 
with 1-3 brain metastases (121 patients, 84.6%) and those 
with >3 metastases (22 patients, 15.4%). WBRT doses ranged 
from 20-30 Gy in 3.0-4.0 Gy per fraction, SBRT was given in 
1-6 fractions (median 1 fraction) of 6-22 Gy (median 15 Gy).  
 
Results: 1-year actuarial overall survival was 8%, 6% and 27% 
for SRT, WBRT and SRT+WBRT respectively. The difference in 
overall survival among 143 patients treated with SRS+WBRT 
vs. SRS or WBRT was highly significant (p<0.0001). The 
difference in overall survival between SRS+WBRT vs. SRS or 
WBRT was also apparent in a subgroup of patients with 1-3 
metastases (1-year OS of 9%, 0% and 26%, respectively). By 
contrast, the differences in OS according to treatment were 
not significant among the patients with >3 metastases. A 
multivariate analysis showed that out of several variables 
considered only WBRT alone or SRT alone (HR=1.85, p=0.001) 
and age over 70 years (HR=2.08, p=0.005) were associated 
with unfavorable survival. 
 
Conclusion: Although conclusions from this study are limited 
by nonrandomized selection of the treatment schedule and 
some heterogeneity in prescription practice the data 
presented suggest that combination of WBRT and SRT vs. 
WBRT alone or SRT alone result in considerably improved 
